ArticleFrontiers in psychiatry2025
Better treatment outcomes with aripiprazole long-acting injection in community and incarcerated patients with serious mental illness.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Aripiprazole, a partial D2 receptor agonist, is proposed to enhance prefrontal cortex (PFC) dopamine function, improving working memory and GABA transmission, which supports social functioning. Long-acting injectable (LAI) antipsychotics are known to improve patient adherence, leading to enhanced long-term effects on behavioral outcomes. Objective: To evaluate whether aripiprazole LAI treatment improves general functioning, quality of life, and reduces hospitalizations in psychotic patients, both in community settings and within incarcerated populations. Design settings and participants: The study included 55 patients, with 34 from the community and 21 incarcerated at a prison in Southeastern Greece (Neapolis). The World Health Organization Quality of Life Brief Version (WHOQOL-BREF) and the Clinical Global Impression-Severity (CGI-S) scale were used to assess outcomes. Comparisons were made between pre-treatment and post-treatment periods, with a minimum follow-up of six months. Results: • Demographics: Community patients (70.6% male) included 44.1% with paranoid schizophrenia. Incarcerated patients (all male) had an F29.0 diagnosis, with 57.1% exhibiting Cluster B personality disorder and all reporting psychoactive substance use.• Hospitalizations: Community patients' hospitalizations decreased from 1.4 to 0.1 over six months (p=0.001). Incarcerated patients' hospitalizations dropped from 0.6 to 0.0 (p=0.066), with no significant intergroup difference (p=0.150).• CGI-S: Community patients' scores improved from 6.0 to 3.9 (p<0.001). Incarcerated patients' scores improved from 5.3 to 3.2 (p<0.001), with no significant difference between groups (p=0.814).• Quality of Life: Community patients' scores rose from 0.5 to 3.0 (p<0.001), while incarcerated patients' scores also increased significantly (p<0.001). Conclusions: This study of 34 community and 21 incarcerated patients revealed significant demographic and medical history differences. Both groups experienced reduced hospitalizations and improvements in CGI-S scores and quality of life following aripiprazole LAI administration. Community patients showed a greater reduction in hospitalizations, while clinical and quality-of-life improvements were comparable across groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.